Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.86 USD
Change Today -0.0672 / -7.23%
Volume 910.6K
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

enzon pharmaceuticals inc (ENZN) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/13/15 - $1.33
52 Week Low
10/14/14 - $0.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

enzon pharmaceuticals inc (ENZN) Related Businessweek News

No Related Businessweek News Found

enzon pharmaceuticals inc (ENZN) Details

Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.

1 Employees
Last Reported Date: 03/5/15
Founded in 1981

enzon pharmaceuticals inc (ENZN) Top Compensated Officers

Principal Financial Officer, Principal Accoun...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

enzon pharmaceuticals inc (ENZN) Key Developments

Enzon Pharmaceuticals Inc. Declares Special Dividend Payable on August 12, 2015

On June 30, 2015, Enzon Pharmaceuticals Inc.'s Board of Directors declared a special cash dividend of $0.50 per share of the Company's common stock, payable on August 12, 2015 to stockholders of record as of July 21, 2015.

Enzon Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2015

Enzon Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2015., at 11:00 US Eastern Standard Time. Location: Club 101 on the Main Floor at 101 Park Avenue. Agenda: To elect three directors, each for a one-year term expiring at its next annual meeting of stockholders and until such director’s successor is elected and qualified; to ratify the adoption of its Section 382 rights agreement, which was previously adopted by its Board of Directors on April 30, 2014 in an effort to protect stockholder value by attempting to protect against a possible limitation on its ability to use its net operating loss carryforwards; to ratify the appointment of EisnerAmper LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2015; to approve, on an advisory basis, the compensation of its named executive officers; and to transact such other matters as may properly come before the 2015 Annual Meeting or any adjournment or postponement thereof.

Enzon Pharmaceuticals Inc. Announces Special Cash Dividend, Payable on January 28, 2015

On December 4, 2014, the Board of Directors of Enzon Pharmaceuticals Inc. declared a special cash dividend of $0.10 per share of the company's common stock, payable on January 28, 2015 to stockholders of record as of January 12, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $0.86 USD -0.0672

ENZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $19.00 USD +0.27
Nektar Therapeutics $11.34 USD +0.56
Onxeo SA €3.80 EUR +0.24
Regulus Therapeutics Inc $6.86 USD +0.29
Veloxis Pharmaceuticals A/S kr1.51 DKK 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ENZN Industry Range
Price/Earnings 1.7x
Price/Sales 1.7x
Price/Book 2.2x
Price/Cash Flow 1.7x
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at